Global health expenditure reached approximately $9.8 trillion, accounting for roughly 10 percent of global GDP, according to World Health Organization data shared by healthcare growth executive Habib Nehmé in a recent industry analysis. Within this massive $10 trillion healthcare economy, spending remains heavily skewed toward delivery systems and basic infrastructure rather than specialized disease targeting.
Where Does the Global Healthcare Dollar Go?
Breaking down the global expenditure reveals stark spending tiers across sectors. According to the data, healthcare delivery and related services consume roughly ~$7.4T, encompassing hospitals, physicians, nurses, long-term care, administration, and facility infrastructure.
Pharmaceuticals and prescription medicines account for approximately ~$1.7T, based on list-price estimates from IQVIA for the global prescription medicine market. Meanwhile, the global MedTech market—covering imaging, in-vitro diagnostics, cardiovascular devices, orthopaedics, surgery, monitoring, diabetes technology, and oncology equipment—represents about ~$650B.
Did You Know?
For every $100 spent on healthcare globally, about $76 goes toward delivery and services, $17 is spent on medicines, and just $6.60 covers MedTech and medical devices.
The Mounting Global Burden of Cancer Care
Cancer stands as the world’s second leading death cause, creating immense human and economic tolls. According to global figures, an estimated 20.6 million people were diagnosed with cancer in 2024, while 9.8 million died from the disease—translating to more than 26,000 deaths every day.
Without major interventions in prevention and cancer control, the WHO projects new cases will surge to 34.4 million annually by 2050, marking a 67 percent increase from 2024 levels. Despite these escalating figures, tracking total cancer spending proves complex because oncology costs disperse across multiple silos, including hospitals, surgery, radiotherapy, imaging, pathology, diagnostics, workforce, and infrastructure.
Pharmaceuticals Versus Total Treatment Ecosystem Costs
Global spending on cancer medicines alone reached approximately ~$291B, which accounts for nearly 17 percent of the entire global pharmaceutical market. However, this ~$291B figure covers strictly the medication component.
The medication total excludes critical diagnostic and treatment tools such as MRIs, CT scans, PET scans, biopsies, pathology services, surgical suites, and robotic systems. It also excludes radiation hardware like LINAC and MR-LINAC machines, specialized medical staff, hospital infrastructure, prevention programs, screening initiatives, and palliative care.
Comparing Oncology Spend to Broader Healthcare Infrastructure
While pharmaceutical investments in oncology claim nearly one-fifth of global medicine spending, the broader care ecosystem receives fragmented funding. Disparities remain severe: low-income countries carry substantial cancer burdens yet possess the least capacity to diagnose and treat patients, leading to drastically lower survival rates, according to WHO reports.
Macroeconomic Impact and the Need for Strategic Allocation
Cancer is projected to impose a $25.2 trillion macroeconomic cost on the global economy between 2020 and 2050, representing an annual economic burden of about 0.55 percent of global GDP. Nehmé argues that the central question is no longer whether the world can afford to spend more on cancer, but whether it can afford not to invest more intelligently.
Optimizing the global health economy requires connecting the entire clinical pathway—from prevention, screening, diagnosis, imaging, and pathology to treatment, radiotherapy, surgery, medicines, monitoring, and follow-up. Leveraging artificial intelligence, data analytics, modern infrastructure, and innovative financing models can make this continuum more accessible, efficient, and affordable.
Frequently Asked Questions
How much does the global healthcare economy spend annually?
Global health expenditure reaches approximately $9.8 trillion, or roughly 10 percent of global GDP, according to World Health Organization data.
What percentage of global pharmaceutical spending goes to cancer medicines?
Global spending on cancer medicines reached approximately ~$291B, accounting for nearly 17 percent of the global pharmaceutical market.
What is the projected economic burden of cancer by 2050?
Cancer is estimated to impose a $25.2 trillion macroeconomic cost on the global economy between 2020 and 2050.
How many new cancer cases are projected annually by 2050?
Without major changes in prevention and control, annual new cancer cases are projected to reach 34.4 million by 2050, a 67 percent increase from 2024.
Join the Healthcare Transformation Conversation
How can healthcare leaders better allocate resources to tackle the rising global burden of cancer? Share your thoughts in the comments below or subscribe to our newsletter for ongoing analysis of global health economics.